Highlights

Raised over $15M to date, including a $4M investment from Synthes (a Johnson & Johnson company) and a successful SeedInvest round in 2019

Executed licensing agreements for sale of its FACT and APIC technologies in the human and veterinary markets, with a value up to $7M and 10% royalties on net sales 

Initiated a pilot pre-clinical study in late 2019 for the lead drug candidate CYT-108, a key milestone on the path to Phase 1 human clinical trials  

IP portfolio consists of 8 issued U.S. and international patents with 9 patents pending   

Founded by a leading orthopedic surgeon (21 years of experience) and backed by renowned physicians, researchers, and biotech investors